Brief: Atossa Therapeutics Issues Letter To Shareholders
25/01/2023 14:17
Jan 25 (Reuters) - Atossa Therapeutics Inc ATOS.O :
* ATOSSA THERAPEUTICS ISSUES LETTER TO SHAREHOLDERS
* ATOSSA THERAPEUTICS - AS WE LOOK FORWARD TO 2023, WE ARE
WELL
POSITIONED TO CONTINUE ACCELERATING DEVELOPMENT OF (Z)-ENDOXIFEN
Source text for Eikon: ID:nGNX4vd08b
Further company coverage: ATOS.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary